

FACTORS IN DEVELOPING INJECTABLE DRUG PLACEBO FORMULATIONS FOR PHARMACEUTICAL CLINICAL TRIALS

Singota® Solutions is a CDMO located in Bloomington, Indiana, USA that specializes in Parenteral, Early Phase Drug Development and Aseptic Filling projects.

Placebo-controlled trials are used to test the effectiveness of newly developed medicines. When designed and conducted properly, they can provide proof that a new drug is effective. Proper and complete understanding of development practices for placebos is very important to the execution and outcomes of clinical trials. This article highlights factors that pharmaceutical scientists must consider when formulating placebos for injectable drugs to ensure the reliability and validity of clinical trial outcomes.

Placebo Product Specifications

Simply put, the goal is to formulate a placebo that mirrors the corresponding active drug's physical characteristics, minus the active ingredient and without any unintended responses in the participants. This can be done by leveraging knowledge of the active product and then developing specifications that clearly define and quantify these characteristics, along with appropriate analytical methods. Physical appearance and handling properties, such as viscosity, appearance, color, and pH, must be specified. Methods must be identified and developed/qualified prior to any product development/testing activities.

Strategies in Formulation and Ingredient Selection

Maintaining the blinding of clinical trial participants and researchers can be a challenge when developing an injectable placebo. The injectable placebo should not only visually match the active product but must mimic injection characteristics observed during administration, such as tactile feel and any associated "burn" during injection.

Typically, the formulation of an injectable placebo can be essentially the same as the active product, less the active pharmaceutical ingredient, combined with some minor changes and excipients to mimic the physical properties of the drug product. The right placebo formulation will cause neither a positive nor a negative result. Some properties can be difficult to mimic. For example, product color that may arise from interaction between the active ingredient with the excipients can be a challenge to duplicate.

Analytical Methods and Stability Studies

Method development and qualifications should be completed prior to commencement of any development activities. Most, if not all of these methods may already be available from the work completed on the active product. The placebo must pass the specification criteria dictated by the given methods.

The laboratory charged with the placebo development must conduct comprehensive stability studies to assess the placebo's resilience under various conditions, including temperature and humidity excursions, light sensitivity, and time at these conditions. Stability testing ensures that the formulation remains consistent throughout the study period, preventing unexpected changes that could compromise the trial's scientific integrity.

Other Considerations

Injectable drugs, whether active or placebo, demand a sterile environment to prevent contamination and ensure participant safety. Laboratories must adhere to good manufacturing practice (GMP) standards, implementing rigorous procedures to maintain sterility and avoid any compromise to the placebo's integrity.

As with the active product formulation, the placebo formulation must be reproducible, and the process must be scalable. As clinical trials progress, the product and process development organization must be equipped to scale up placebo production while maintaining formulation consistency. Reproducibility of the placebo formulation is crucial to ensure that results obtained in the laboratory setting are translatable to larger-scale production for widespread clinical use.

Rigorous documentation of the formulation process is essential for regulatory approval just the same as for an active product. The laboratory must maintain comprehensive records detailing the selection of ingredients, batch records, manufacturing processes, and quality control procedures. Compliance with regulatory guidelines, such as GMP, ensures that the placebo formulation meets the stringent standards set forth by regulatory authorities. Post-filling sterilization techniques need to be considered as well.



www.singota.com





Summary

Developing a placebo for an injectable drug is a multidimensional effort that requires appreciation of the formulation's impact in the trials, attention to the chemistry and physical details, adherence to ethical standards, and compliance with regulatory guidelines. Biotech firms using CDMOs for developing injectable placebos need to be aware of these factors. 4 With attention paid to excipient selection, blinding strategies, sterile techniques, stability studies, quality control, documentation, ethical considerations, and scalability, researchers can navigate placebo formulation, contributing to success of pharmaceutical clinical trials. In doing so, the development group tasked with placebo development performs an important role in the innovation and advancement of injectable drug development.

Singota Solutions is a US based CDMO in Bloomington, Indiana. Singota specializes in formulation development and aseptic fill finish for injectable projects. Once a formulation is established, Singota utilizes state of the art robotic filling technology and focuses on smaller batch size requirements. For more information, visit Singota.com to explore how Singota has established itself as a one-stop solution for all your developmental needs.

Contact solutions@singota.com to schedule a meeting with our business development team to further discuss your current or future projects.